Targeting Bcl-2 Proteins in Acute Myeloid Leukemia

B cell lymphoma 2 (BCL-2) family proteins play an important role in intrinsic apoptosis. Overexpression of BCL-2 proteins in acute myeloid leukemia can circumvent resistance to apoptosis and chemotherapy. Considering this effect, the exploration of anti-apoptotic BCL-2 inhibitors is considered to ha...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 10; p. 584974
Main Authors Wei, Yunxiong, Cao, Yaqing, Sun, Rui, Cheng, Lin, Xiong, Xia, Jin, Xin, He, Xiaoyuan, Lu, Wenyi, Zhao, Mingfeng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 05.11.2020
Subjects
AML—acute myeloid leukemia
B cell lymphoma 2
Bcl-2 protein
intrinsic apoptosis
Oncology
venetoclax (ABT-199)
B cell lymphoma 2
intrinsic apoptosis
Bcl-2 protein
venetoclax (ABT-199)
AML—acute myeloid leukemia
Online AccessGet full text

Cover

More Information
Summary:B cell lymphoma 2 (BCL-2) family proteins play an important role in intrinsic apoptosis. Overexpression of BCL-2 proteins in acute myeloid leukemia can circumvent resistance to apoptosis and chemotherapy. Considering this effect, the exploration of anti-apoptotic BCL-2 inhibitors is considered to have tremendous potential for the discovery of novel pharmacological modulators in cancer. This review outlines the impact of BCL-2 family proteins on intrinsic apoptosis and the development of acute myeloid leukemia (AML). Furthermore, we will also review the new combination therapy with venetoclax that overcomes resistance to venetoclax and discuss biomarkers of treatment response identified in early-phase clinical trials.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
Edited by: Naval Daver, University of Texas MD Anderson Cancer Center, United States
Reviewed by: Luca Maurillo, University of Rome Tor Vergata, Italy; Michael Diamantidis, University Hospital of Larissa, Greece
This article was submitted to Hematologic Malignancies, a section of the journal Frontiers in Oncology
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.584974